GlassScriptPhysician profile
Ritwik Grover
NPI 1609211424
$2,978.10
in general payments reported to CMS, 2019-2025
31 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.09 · 2020: $121 · 2021: $1,719 · 2022: $236 · 2023: $257 · 2024: $144 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $1,092.00 | 2021 | |
| Mentor Worldwide LLC | $453.17 | 2021-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Sientra, INC. | $297.95 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $130.96 | 2022-2025 | |
| Acell, INC. | $104.73 | 2020 | |
| Esperion Therapeutics, INC. | $101.91 | 2021 | |
| Convatec INC. | $95.10 | 2025 | |
| Abbvie INC. | $65.74 | 2021-2025 | |
| Novo Nordisk INC | $63.77 | 2021-2023 | Wegovy |
| Baxter Healthcare | $43.86 | 2023 | |
| Axogen | $39.09 | 2019 | |
| Organogenesis INC. | $38.85 | 2025 | Affinity |
| Davol INC. | $35.09 | 2025 | Phasix Mesh |
| Astrazeneca Pharmaceuticals LP | $34.48 | 2021 | |
| Medtronic, INC. | $32.84 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Checkpoint Surgical, INC | $32.24 | 2022 | |
| Integra Lifesciences Corporation | $31.13 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Solventum Corporation | $30.34 | 2025 | Prevena |
| Acera Surgical, INC. | $29.79 | 2025 | Restrata Wound Matrix |
| Kerecis Limited | $25.77 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Polynovo North America LLC | $21.70 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $20.25 | 2021 | |
| Allergan, INC. | $19.76 | 2022 | |
| Phadia US INC. | $19.48 | 2024 | Immunocap |
| Amarin Pharma, INC. | $19.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.14 | 2021 | |
| Mannkind Corporation | $18.06 | 2021 | |
| Motiva USA, LLC | $17.60 | 2025 | |
| Amgen INC. | $16.35 | 2020 | |
| Galderma Laboratories, L.P. | $14.46 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritwik Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.